(R) -Simurosertib
(R) -Simurosertib ((R) -TAK-931) is the (R) -enantiomer of Simurosertib. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of [1].
Product Specifications
CAS Number
[1330782-69-8]
Product Name Alternative
(R) -TAK-931
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Neuroscience-Neuromodulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/r-simurosertib.html
Concentration
10mM
Purity
99.58
Solubility
DMSO : 75 mg/mL (ultrasonic)
Smiles
O=C(C1=C(N2)C=C(C3=CNN=C3C)S1)N=C2[C@H]4CC5CCN4CC5
Molecular Formula
C17H19N5OS
Molecular Weight
341.43
References & Citations
[1]K Iwai, et al. A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity. European Journal of Cancer , 2016 , 69 (1) :S34.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Tetratricopeptide Repeat Protein 3 (TPR Repeat Protein 3, TTC3, E3 Ubiquitin-protein Ligase TTC3, DCRR1, Protein DCRR1, RING Finger Protein 105, RNF105, TPR Repeat Protein D, TPRD, TPRDIII) (AP)
Tetratricopeptide Repeat Protein 3 (TPR Repeat Protein 3, TTC3, E3 Ubiquitin-protein Ligase TTC3, DCRR1, Protein DCRR1, RING Finger Protein 105, RNF105, TPR Repeat Protein D, TPRD, TPRDIII) (AP)
Moesin (Membrane-organizing extension spike protein, Moesin/anaplastic lymphoma kinase fusion protein, MSN/ALK fusion) (FITC)